

June 30, 2021

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Regarding a judgment on the violation of the Antimonopoly Act

Today, our consolidated subsidiary, TOHO PHARMACEUTICAL CO., LTD., and our employee were sentenced by the Tokyo District Court to a fine of 250 million yen and to a suspended sentence for violating the Antimonopoly Act in connection with bidding on the supply of ethical pharmaceuticals to the Japan Community Health care Organization (JCHO).

This is truly regrettable situation and we sincerely apologize for causing any concern and inconvenience to our shareholders and other related stakeholders.

The Group takes this judgment very seriously and makes every effort to restore trust, while making company-wide efforts to strengthen compliance in order to prevent a recurrence of similar incidents, announced in December 2020.